Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Kalaris Therapeutics announced positive Phase 1a data for TH103, its investigational treatment for neovascular AMD. The expanded trial of 17 treatment-naive patients showed improvements in vision and retinal anatomy, with 29% requiring no additional anti-VEGF treatment during six-month follow-up. TH103 demonstrated 27-53 fold lower plasma levels compared to leading anti-VEGF agents while maintaining efficacy. The company is actively enrolling patients in Phase 1b/2 trials with preliminary data expected in H1 2027.